Abstract
People living with rheumatic diseases frequently encounter cancer, either as a potential harm of antirheumatic therapies or as a comorbidity that alters the conversation about management. This article provides a general overview of the issues related to cancer and rheumatic disease and serves as a springboard for the remaining chapters in this issue. Several topics are reviewed, including epidemiology, bidirectional causal pathways, and issues related to medications. Although uncertainties remain, the issue of cancer is of great importance to patients with rheumatic diseases, and an individualized, person-centered approach to assessment and management is necessary.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 417-427 |
| Number of pages | 11 |
| Journal | Rheumatic Disease Clinics of North America |
| Volume | 46 |
| Issue number | 3 |
| DOIs | |
| State | Published - Aug 2020 |
Keywords
- Biologic therapies
- Cancer
- Immune checkpoint inhibitors
- Immune-related adverse events
- Malignancy
- Prognosis
- Rheumatic disease
- Treatment
ASJC Scopus subject areas
- Rheumatology